Literature DB >> 21080416

Acamprosate in the treatment of binge eating disorder: a placebo-controlled trial.

Susan L McElroy1, Anna I Guerdjikova, Erin L Winstanley, Anne M O'Melia, Nicole Mori, Jessica McCoy, Paul E Keck, James I Hudson.   

Abstract

OBJECTIVE: To assess preliminarily the effectiveness of acamprosate in binge eating disorder (BED).
METHOD: In this 10-week, randomized, placebo-controlled, flexible dose trial, 40 outpatients with BED received acamprosate (N = 20) or placebo (N = 20). The primary outcome measure was binge eating episode frequency.
RESULTS: While acamprosate was not associated with a significantly greater rate of reduction in binge eating episode frequency or any other measure in the primary longitudinal analysis, in the endpoint analysis it was associated with statistically significant improvements in binge day frequency and measures of obsessive-compulsiveness of binge eating, food craving, and quality of life. Among completers, weight and BMI decreased slightly in the acamprosate group but increased in the placebo group. DISCUSSION: Although acamprosate did not separate from placebo on any outcome variable in the longitudinal analysis, results of the endpoint and completer analyses suggest the drug may have some utility in BED.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21080416     DOI: 10.1002/eat.20876

Source DB:  PubMed          Journal:  Int J Eat Disord        ISSN: 0276-3478            Impact factor:   4.861


  24 in total

1.  Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial.

Authors:  Marney A White; Carlos M Grilo
Journal:  J Clin Psychiatry       Date:  2013-04       Impact factor: 4.384

Review 2.  Pharmacological treatment of binge eating disorder: update review and synthesis.

Authors:  Deborah L Reas; Carlos M Grilo
Journal:  Expert Opin Pharmacother       Date:  2015-06-04       Impact factor: 3.889

Review 3.  Current and emerging drug treatments for binge eating disorder.

Authors:  Deborah L Reas; Carlos M Grilo
Journal:  Expert Opin Emerg Drugs       Date:  2014-01-25       Impact factor: 4.191

Review 4.  The clinical pharmacology of acamprosate.

Authors:  Nicola J Kalk; Anne R Lingford-Hughes
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

5.  Pharmacotherapies for Overeating and Obesity.

Authors:  S Yarnell; M Oscar-Berman; Nm Avena; K Blum; Ms Gold
Journal:  J Genet Syndr Gene Ther       Date:  2013-04-01

Review 6.  Progress in Developing Pharmacologic Agents to Treat Bulimia Nervosa.

Authors:  Susan L McElroy; Anna I Guerdjikova; Nicole Mori; Francisco Romo-Nava
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

7.  Pharmacological approaches to the management of binge eating disorder.

Authors:  Kimberly A Brownley; Christine M Peat; Maria La Via; Cynthia M Bulik
Journal:  Drugs       Date:  2015-01       Impact factor: 9.546

8.  Treatment of Binge Eating Disorder.

Authors:  Scott Crow
Journal:  Curr Treat Options Psychiatry       Date:  2014-12

Review 9.  Pharmacological means of reducing human drug dependence: a selective and narrative review of the clinical literature.

Authors:  Shih-Ku Lin
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 10.  Binge-Eating Disorder in Adults: A Systematic Review and Meta-analysis.

Authors:  Kimberly A Brownley; Nancy D Berkman; Christine M Peat; Kathleen N Lohr; Katherine E Cullen; Carla M Bann; Cynthia M Bulik
Journal:  Ann Intern Med       Date:  2016-06-28       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.